- Home
- WST vs GMAB Comparison
WST vs GMAB Comparison
Compare WST & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WST
- GMAB
- Stock Information
- Founded
- WST 1923
- GMAB 1999
- Country
- WST United States
- GMAB Denmark
- Employees
- WST N/A
- GMAB N/A
- Industry
- WST Medical/Dental Instruments
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- WST Health Care
- GMAB Health Care
- Exchange
- WST Nasdaq
- GMAB Nasdaq
- Market Cap
- WST 20.1B
- GMAB 17.4B
- IPO Year
- WST N/A
- GMAB N/A
- Fundamental
- Price
- WST $299.62
- GMAB $29.93
- Analyst Decision
- WST Strong Buy
- GMAB Strong Buy
- Analyst Count
- WST 8
- GMAB 7
- Target Price
- WST $348.00
- GMAB $41.17
- AVG Volume (30 Days)
- WST 707.3K
- GMAB 3.1M
- Earning Date
- WST 10-23-2025
- GMAB 11-06-2025
- Dividend Yield
- WST 0.30%
- GMAB N/A
- EPS Growth
- WST 0.17
- GMAB 77.72
- EPS
- WST 6.75
- GMAB 21.62
- Revenue
- WST $3,017,900,000.00
- GMAB $3,646,881,232.00
- Revenue This Year
- WST $6.49
- GMAB $24.25
- Revenue Next Year
- WST $6.23
- GMAB $16.29
- P/E Ratio
- WST $44.06
- GMAB $13.36
- Revenue Growth
- WST 4.92
- GMAB 32.97
- 52 Week Low
- WST $187.43
- GMAB $17.24
- 52 Week High
- WST $352.33
- GMAB $33.65
- Technical
- Relative Strength Index (RSI)
- WST 72.87
- GMAB 46.39
- Support Level
- WST $260.12
- GMAB $29.57
- Resistance Level
- WST $322.34
- GMAB $30.24
- Average True Range (ATR)
- WST 7.39
- GMAB 0.67
- MACD
- WST 3.28
- GMAB -0.58
- Stochastic Oscillator
- WST 64.97
- GMAB 11.11
About WST West Pharmaceutical Services Inc.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.